Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gains from Sales and Divestitures (2016 - 2025)

Lineage Cell Therapeutics' Gains from Sales and Divestitures history spans 15 years, with the latest figure at $86000.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 28.36% year-over-year to $86000.0; the TTM value through Dec 2025 reached $86000.0, up 28.36%, while the annual FY2025 figure was $86000.0, 28.36% up from the prior year.
  • Gains from Sales and Divestitures reached $86000.0 in Q4 2025 per LCTX's latest filing, up from $67000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $86000.0 in Q4 2025 to a low of $16000.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 5 years is $57000.0, with a median of $67000.0 recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: tumbled 50.0% in 2022, then skyrocketed 400.0% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $62000.0 in 2021, then crashed by 50.0% to $31000.0 in 2022, then surged by 158.06% to $80000.0 in 2023, then dropped by 16.25% to $67000.0 in 2024, then grew by 28.36% to $86000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Gains from Sales and Divestitures are $86000.0 (Q4 2025), $67000.0 (Q3 2025), and $67000.0 (Q2 2025).